Experimental Design, a Key Component in Drug Development
Monday 2 June, 1:20--2:20
- Organizer: Frank SHEN
- Bristol-Myers Squibb
- Moderator: Frank SHEN
- Bristol-Myers Squibb
- Randolph L. GREASHAM
- Merck and Co., Inc., Rahway, NJ, USA
A large number of important pharmaceutical drugs is produced either
fully (such as MEVACOR) or partially (as key chemical intermediates;
ZOCOR) by microorganisms. These compounds as well as the microorganisms
that produce them are usually identified through extensive screening
programs. Once a product candidate is identified, a process to produce
this compound in large quantities must be rapidly developed to support
chemical modification and safety assessment studies. The number of
environmental parameters important to microbial growth and product
synthesis is quite great, including both chemical (such as nutrient
requirements) and physical (such as temperature and pH) factors.
Therefore, the employment of a full factorial search is often too time
consuming, requiring for example a total of 729 separate experimental
trials to evaluate six nutrients at three concentrations. To achieve
enhanced productivities in a timely manner, a combination of partial
factorial searches (such as Plackett-Burman and Box-Behnken designs) and
pattern searches (such as the sequential simplex method) are frequently
employed.
[Randolph L. GREASHAM, Merck and Co., Inc., Rahway, NJ, randolph\_greasham@merck.com]
Back to JRC program
Back to JRC Home Page